Isath Ameesh, Ohira Suguru, Levine Avi, Pan Stephen, Aggarwal-Gupta Chhaya, Lanier Gregg M, Wolfe Kevin, Spielvogel David, Gass Alan, Kai Masashi
Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Division of Cardiothoracic Surgery, Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, NY.
Transplant Direct. 2023 Feb 22;9(3):e1455. doi: 10.1097/TXD.0000000000001455. eCollection 2023 Mar.
Scarcity of donor hearts continues to be a challenge for heart transplantation (HT). The recently Food and Drug Administration-approved Organ Care System (OCS; Heart, TransMedics) for ex vivo organ perfusion enables extension of ex situ intervals and thus may expand the donor pool. Because postapproval real-world outcomes of OCS in HT are lacking, we report our initial experience.
We retrospectively reviewed consecutive patients who received HT at our institution in the post-Food and Drug Administration approval period from May 1 to October 15, 2022. Patients were divided into 2 groups: OCS versus conventional technique. Baseline characteristics and outcomes were compared.
A total of 21 patients received HT during this period, 8 using OCS and 13 conventional techniques. All hearts were from donation after brain death donors. The indication for OCS was an expected ischemic time of >4 h. Baseline characteristics in the 2 groups were comparable. The mean distance traveled for heart recovery was significantly higher in the OCS group (OCS, 845 ± 337, versus conventional, 186 ± 188 mi; < 0.001), as was the mean total preservation time (6.5 ± 0.7 versus 2.5 ± 0.7 h; < 0.001). The mean OCS time was 5.1 ± 0.7 h. In-hospital survival in the OCS group was 100% compared with 92.3% in the conventional group ( = 0.32). Primary graft dysfunction was similar in both groups (OCS 12.5% versus conventional 15.4%; = 0.85). No patient in the OCS group required venoarterial extracorporeal membrane oxygenation support after transplant compared with 1 in the conventional group (0% versus 7.7%; = 0.32). The mean intensive care unit length of stay after transplant was comparable.
OCS allowed utilization of donors from extended distances that otherwise would not be considered because ischemic time would be prohibitive by conventional technique.
供体心脏的稀缺仍然是心脏移植(HT)面临的一项挑战。美国食品药品监督管理局最近批准的用于离体器官灌注的器官护理系统(OCS;心脏,TransMedics)能够延长体外保存时间,因此可能会扩大供体库。由于缺乏OCS在心脏移植中获批后的真实世界结果,我们报告了我们的初步经验。
我们回顾性分析了在2022年5月1日至10月15日美国食品药品监督管理局批准后期间在我们机构接受心脏移植的连续患者。患者分为两组:OCS组与传统技术组。比较了基线特征和结果。
在此期间共有21例患者接受了心脏移植,8例使用OCS,13例采用传统技术。所有心脏均来自脑死亡供体的捐赠。使用OCS的指征是预期缺血时间>4小时。两组的基线特征具有可比性。OCS组心脏获取的平均运输距离显著更长(OCS组为845±337英里,传统技术组为186±188英里;P<0.001),平均总保存时间也是如此(6.5±0.7小时对2.5±0.7小时;P<0.001)。OCS的平均时间为5.1±0.7小时。OCS组的院内生存率为100%,而传统组为92.3%(P=0.32)。两组的原发性移植物功能障碍相似(OCS组为12.5%,传统组为...